Cargando…

Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use

BACKGROUND: Patients with juvenile idiopathic arthritis (JIA) on non-steroidal anti- inflammatory drugs (NSAIDs) may experience abdominal pain. In adults, NSAID use has been linked to an increase in fecal calprotectin (FC) levels, a surrogate marker for gut inflammation. In JIA, data on gut inflamma...

Descripción completa

Detalles Bibliográficos
Autores principales: Aalto, Kristiina, Lahdenne, Pekka, Kolho, Kaija-Leena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286851/
https://www.ncbi.nlm.nih.gov/pubmed/28143478
http://dx.doi.org/10.1186/s12969-016-0132-2
_version_ 1782504077566935040
author Aalto, Kristiina
Lahdenne, Pekka
Kolho, Kaija-Leena
author_facet Aalto, Kristiina
Lahdenne, Pekka
Kolho, Kaija-Leena
author_sort Aalto, Kristiina
collection PubMed
description BACKGROUND: Patients with juvenile idiopathic arthritis (JIA) on non-steroidal anti- inflammatory drugs (NSAIDs) may experience abdominal pain. In adults, NSAID use has been linked to an increase in fecal calprotectin (FC) levels, a surrogate marker for gut inflammation. In JIA, data on gut inflammation related to drug use is scarce. METHODS: JIA patients followed up at the outpatient pediatric rheumatology clinic in Children’s Hospital, Helsinki University Hospital, Helsinki, Finland were routinely assessed for FC if they complained about abdominal pain, had an elevated erythrocyte sedimentation rate (ESR) or used NSAIDs on a daily basis. The FC levels were related to the presence of abdominal pain, to ESR, and to the presence of HLA-B27. RESULTS: Of the total group of 90 patients (median age 9.1 years; 45 JIA patients with disease modifying anti-rheumatic drugs (DMARDs), 25 without DMARD medication, and 20 arthralgia patients as controls), approximately 50% used NSAIDs, of whom 40% complained about abdominal pain. In patients with abdominal pain, one-third had elevated FC values (>100 μg/g). The FC values, for the most part, declined along with the discontinuation or reduction of NSAIDs and after intensifying the DMARD medication, where after the pain disappeared. In patients with an elevated ESR, the FC values and ESR normalized in parallel. The presence of HLA-B27 was not associated with FC levels. CONCLUSION: In patients with JIA and abdominal pain, it may be useful to determine the FC when evaluating the need for further gastrointestinal examinations.
format Online
Article
Text
id pubmed-5286851
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-52868512017-02-06 Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use Aalto, Kristiina Lahdenne, Pekka Kolho, Kaija-Leena Pediatr Rheumatol Online J Research Article BACKGROUND: Patients with juvenile idiopathic arthritis (JIA) on non-steroidal anti- inflammatory drugs (NSAIDs) may experience abdominal pain. In adults, NSAID use has been linked to an increase in fecal calprotectin (FC) levels, a surrogate marker for gut inflammation. In JIA, data on gut inflammation related to drug use is scarce. METHODS: JIA patients followed up at the outpatient pediatric rheumatology clinic in Children’s Hospital, Helsinki University Hospital, Helsinki, Finland were routinely assessed for FC if they complained about abdominal pain, had an elevated erythrocyte sedimentation rate (ESR) or used NSAIDs on a daily basis. The FC levels were related to the presence of abdominal pain, to ESR, and to the presence of HLA-B27. RESULTS: Of the total group of 90 patients (median age 9.1 years; 45 JIA patients with disease modifying anti-rheumatic drugs (DMARDs), 25 without DMARD medication, and 20 arthralgia patients as controls), approximately 50% used NSAIDs, of whom 40% complained about abdominal pain. In patients with abdominal pain, one-third had elevated FC values (>100 μg/g). The FC values, for the most part, declined along with the discontinuation or reduction of NSAIDs and after intensifying the DMARD medication, where after the pain disappeared. In patients with an elevated ESR, the FC values and ESR normalized in parallel. The presence of HLA-B27 was not associated with FC levels. CONCLUSION: In patients with JIA and abdominal pain, it may be useful to determine the FC when evaluating the need for further gastrointestinal examinations. BioMed Central 2017-01-31 /pmc/articles/PMC5286851/ /pubmed/28143478 http://dx.doi.org/10.1186/s12969-016-0132-2 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Aalto, Kristiina
Lahdenne, Pekka
Kolho, Kaija-Leena
Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title_full Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title_fullStr Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title_full_unstemmed Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title_short Fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
title_sort fecal calprotectin in juvenile idiopathic arthritis patients related to drug use
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5286851/
https://www.ncbi.nlm.nih.gov/pubmed/28143478
http://dx.doi.org/10.1186/s12969-016-0132-2
work_keys_str_mv AT aaltokristiina fecalcalprotectininjuvenileidiopathicarthritispatientsrelatedtodruguse
AT lahdennepekka fecalcalprotectininjuvenileidiopathicarthritispatientsrelatedtodruguse
AT kolhokaijaleena fecalcalprotectininjuvenileidiopathicarthritispatientsrelatedtodruguse